Brief: Sutro Biopharma Announces Strategic Portfolio Review Resulting In The Prioritization Of Its Next-Generation Adc Pipeline

Sutro Biopharma

13/03/2025 21:34

March 13 (Reuters) - Sutro Biopharma Inc STRO.O:

SUTRO BIOPHARMA ANNOUNCES STRATEGIC PORTFOLIO REVIEW RESULTING IN THE PRIORITIZATION OF ITS NEXT-GENERATION ADC PIPELINE

SUTRO BIOPHARMA INC - INTENDS TO EXIT ITS INTERNAL GMP MANUFACTURING FACILITY BY YEAR-END

SUTRO BIOPHARMA INC - JANE CHUNG, PRESIDENT AND COO, TO SUCCEED BILL NEWELL AS CEO AND BOARD DIRECTOR

SUTRO BIOPHARMA INC - WILL REDUCE ITS ORGANIZATIONAL HEADCOUNT BY NEARLY 50 PERCENT

SUTRO BIOPHARMA INC -  CASH PAYMENTS ASSOCIATED WITH RESTRUCTURING ARE ESTIMATED TO BE $40 TO $45 MILLION

Source text: ID:nGNX3d7Rq8

Further company coverage: STRO.O

 ((Reuters.Briefs@thomsonreuters.com;))